Elevated levels of circulated vitamin D binding protein (VDBP) may be associated with a decreased risk of prostate cancer (PCa) in black men independent of 25-hydoxyvitamin D status, according to a new study.
Tracy M. Layne, MPH, PhD, of the Yale School of Public Health in New Haven, Connecticut, and the National Cancer Institute in Bethesda, Maryland, and colleagues studied 678 black men participating in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. The group incuded 226 men with PCa and 452 controls matched by age at randomization, date of blood draw, calendar year of cohort entry, and time since baseline PCa screening.
Serum 25-hydroxvitamin D—25(OH)D—was not associated with overall PCa risk, but serum DBP was significantly inversely associated with PCa risk. Men in the highest quartile of VDBP level had 55% decreased odds of PCa compared with those in the lowest quartile, the investigators reported in a paper published online ahead of print in Cancer. The results were similar after mutually adjusting for 25(OH)D and VDBP. The investigators reported finding no evidence of interaction between the two.
1. Layne TM, Weinstein SJ, Graubard BI, et al. Serum 25-hydroxyvitamin D, vitamin D binding protein, and prostate cancer risk in black men. Cancer 2017; published online ahead of print.